MedTrace Logo

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

NCT05481333 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-07-24

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN7999 in healthy adult participants.

The secondary objectives of the study are:

* To characterize the drug concentration profile of single doses of IV or SC REGN7999
* To assess the immunogenicity of single ascending SC or IV doses of REGN7999

Conditions

  • Healthy

Interventions

DRUG

REGN7999

Ascending IV or SC dose administered per protocol

DRUG

Placebo

Ascending IV or SC dose administered per protocol

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-24
Primary Completion
2023-08-29
Completion
2023-08-29

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05481333 on ClinicalTrials.gov